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conventional approaches, including tumor-selective replication, post-cytolysis viral spread between tumor cells, an excellent safety profile, and the potential to stimulate an antitumor response by the host's immune system. 14 However, the overwhelming preclinical success has failed to translate into the clinic, and one major issue is the lack of appropriate immune-competent preclinical models.
We have reported on the therapeutic efficacy of a recombinant Edmonston vaccine strain of measles virus (MV) in mouse orthotopic models of medulloblastoma. 15 In those studies, both irradiated severe combined immunodeficient (SCID) and athymic nude mice implanted with cells from human-derived medulloblastoma cell lines in the caudate/putamen demonstrated significantly increased survival when treated with a recombinant MV compared with those mice treated with an ultraviolet-inactivated form of the virus. Similarly, we have shown that medulloblastoma cells injected into the lateral ventricle of immune deficient mice show growth of tumor that recapitulates CSF disseminated disease in patients. 16 Using this model, we have demonstrated that injection of MV into the lateral ventricle 3 or 14 days after injection of tumor cells significantly prolongs survival. We also showed that tumor cells in the lumbar subarachnoid space stained for viral N protein, indicating that the virus was capable of circulating throughout the subarachnoid space.
Unfortunately, MV does not grow well in murine cells. The first reason for the resistance of murine cells is the lack of a receptor for the virus. This issue has been overcome by the development of a transgenic mouse that expresses high levels of human CD46, the preferred receptor for the Edmonston strain of MV. [17] [18] [19] However, though CD46 facilitates cellular entry of the virus, MV still does not replicate well in cells from this transgenic line. In the normal course of infection, MV makes a protein (V protein) that binds to and inactivates the human Stat1/Stat2 complex. 20, 21 The V protein does not bind to the murine complex. Because Stat1/Stat2 complex activation by interferon results in transcription of antiviral proteins, replication of MV in murine cells, in which the Stat1/Stat2 complex remains active, is prevented. The Sendai virus homolog of the V protein, the Sendai virus C protein (SVC), does bind to and inactivate the murine Stat1/Stat2 complex. 22, 23 In this paper, we take advantage of this property of SVC to manufacture a murine model of Group 3 medulloblastoma that is tumorigenic in immune-competent mice, that is infected by MV, that is permissive for the replication of MV, and that is killed by MV. We chose to model Group 3 medulloblastoma as this subgroup has the worst prognosis and poorest outcome of the 4 molecular subtypes of medulloblastoma. 24 Overexpression and/or amplification of MYC has been frequently implicated as a driver of Group 3 tumors. Recently, Northcott et al have shown that simultaneous expression of MYC with GFI1 or GFI1B, growth factor independence 1 proteins, was sufficient to form Group 3 tumors. 25 To manufacture this model, cerebellar stem cells from human CD46 transgenic mice were transduced to express SVC and to overexpress stabilized c-Myc and Gfi1b proteins. A cell line was established (CSCG cells) that forms medulloblastoma-like tumors when injected into the brain of syngeneic CD46-transgenic mice. CSCG cells are highly proliferative, express stem cell markers, and express the markers of Group 3 medulloblastoma. This cell line allows replication of and is killed by MV, and a single intratumoral injection of MV significantly increased survival of tumorbearing animals compared with control groups in vivo.
Materials and Methods

Preparation of CSCG Cell Line and Mouse Model
Animal-related procedures were performed according to guidelines of the Institutional Animal Care and Use Committee at UCSF. Immune-competent transgenic mice expressing human CD46 (hCD46TgIC) were obtained from the Mayo Clinic and bred at UCSF. The cerebella from five 6-days-old pups were minced, digested with papain, and filtered through a 40 μm cell strainer. Cells formed neurospheres on an ultra-low attachment surface (Corning) in Neurobasal-A (NBA) medium containing B-27 and N2 growth supplements (Life Technologies), epidermal growth factor (EGF) (Sigma-Aldrich) and basic fibroblast growth factor (bFGF) 2 (Miltenyi Biotec) (NBA media). Spheres were dissociated with Accumax (Innovative Cell Technologies), and cells expressing prominin-1 (Prom1; Miltenyi Biotec) were sorted by fluorescence activated cell sorting (FACS) as previously described. 26 Prom1+ cerebellar stem cells were transduced with a lentivirus to express SVC, and firefly luciferase (System Biosciences) and transformed cells were selected with Geneticin-418 (400 μg/mL) antibiotic (CS cells). Next, the CS cells were co-transduced with retroviruses encoding a stabilized form of murine Myc (Myc T58A ) and
Importance of the study
Oncolytic viruses (OV) have advantageous properties such as tumor-specific growth, replication, spread of viruses between tumor cells, and potential stimulation of systemic anticancer immune responses. However, the efficacy of OV in the clinical setting has not fulfilled the promise suggested by preclinical studies. One major reason may be that most preclinical studies are performed on xenograft models in immune-deficient hosts with intratumoral injection of viruses. Because anti-viral immunity is prevalent in the human population, results from immunodeficient models may not translate to human disease. In this paper, we describe the development of a murine Group 3 medulloblastoma cell line that is infectable by MV, allows replication of MV, and is tumorigenic when injected into the brain of immune-competent mice. The CSCG tumor is killed by MV in vitro and in vivo. In addition, this is the first MV-sensitive murine tumor model of any type that grows in immune-competent mice.
murine Gfi1b in conjugation with tdTomato (tdT) and green fluorescent protein (GFP) markers, respectively. 25 Cells double positive for tdT and GFP were flow-sorted and maintained in NBA media with G-418 (200 μg/mL). The stable expression of Myc and Gfi1b was monitored by florescence microscopy. To make a tumorigenic cell line, transformed cells were implanted in the cerebellum of immunodeficient NSG (NOD-scid IL2Rgamma null ) mice using stereotaxic guidance, and tumor growth was measured with luciferase bioluminescence intensity (BLI). Tumor cells were harvested and a cell line, called CSCG, was established.
In Vitro Cell Killing and Virus Replication 
In Vivo Model
CSCG cells (2 × 10 5 per mouse) were injected into the caudate putamen (2 mm lateral of bregma at a depth of 3 mm from the skull) of 7-to 8-week-old hCD46TgIC mice. When the BLI increased by 10-to 20-fold higher than the initial value, animals were randomized into 3 treatment groups. A single intratumoral injection of phosphate buffered saline (PBS), 1.5 × 10 5 TCID 50 of heat-inactivated MV-GFP (HI-MV), or 1.5 × 10 5 TCID 50 of live MV-GFP was given in 6 μL volume. For heat inactivation, virus was incubated at 70°C for 20 min, and the loss of cellular infectivity was verified in vitro (data not shown). Animals were imaged weekly for tumor cell bioluminescence using the Xenogen IVIS Spectrum instrument (Caliper Life Sciences).
Intracellular Flow Cytometry
Cells were dissociated with Accumax, washed with PBS, fixed with 2% paraformaldehyde at room temperature (RT) for 15 min, and permeabilized with −20°C methanol for 15 min on ice. After washing with staining buffer (PBS + 0.1% Tween 20 + 1% bovine serum albumin) and centrifugation at 500 × g, cells were incubated with PBS containing 5% normal goat serum and 0.5% bovine serum albumin for 45 min to block nonspecific staining. Cells were stained with unconjugated primary antibodies for 60 min at 4°C followed by Alexa Fluor 647-conjugated secondary antibody incubation for 45 min at 4°C. Unbound antibody was washed off and cells were analyzed on the BD FACS Calibur flow cytometry system.
Immunostaining
For immunohistochemistry, brains were fixed overnight at 4°C in 10% formalin solution and then stored at 4°C in 70% ethanol. After paraffin-embedding, 5-µm-thick sections were affixed on glass slides and stored at −20°C. For staining, tissues were deparaffinized in xylenes, rehydrated in ethanol gradient (100%-25%) and water, and then subjected to heatinduced epitope retrieval using citrate buffer, pH 6.0 (#C999, Sigma-Aldrich) in a decloaking chamber (Biocare Medical) at 20 psi for 25 minutes. Slides were incubated with 10% goat serum for 1 h at RT to block nonspecific binding, followed by overnight incubation with primary antibodies at 4°C in a moist chamber. Antibodies used were anti-natriuretic peptide receptor 3 (NPR3) (1:200, Abcam, #ab37617), anti-gamma-aminobutyric acid receptor alpha 5 (GABRA5) (1:100, Abcam, #ab10098), and rabbit immunoglobulin G (IgG) isotype control (1:100, Abcam, #ab37415). After washing with Tris-buffer with 0.1% Tween-20, slides were incubated in 3% H 2 O 2 for 10 minutes, washed, and then incubated in horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Signal Stain Boost IHC Detection Reagent, HRP, Rabbit #8114, Cell Signaling Technology) at RT for 45 minutes. Diaminobenzidine solution (SignalStain DAB Detection Kit, #8059, Cell Signaling Technology) was applied for 3-5 min. Tissues were then counterstained in Mayer's hematoxylin for 1 min. After washing with water, all samples were dehydrated in ethanol (25%-100%) and xylenes for mounting using cytoseal 60 media. For immunoflorescence staining, sterile coverslips in a 24-well plate were coated with 0.1% poly-L-lysine (Sigma-Aldrich) for 1 h at RT. After dissociation of neurospheres with Accumax, single cells were added to coverslips for 4 h at 37°C. Adhered cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.25% Triton X-100 for 10 min, and blocked using 5% normal goat serum for 1 h. Primary antibodies were incubated overnight at 4°C, washed and incubated with a fluorophore-conjugated secondary antibody for 1 h at RT. Coverslips were mounted on glass slides with ProLong Gold antifade media containing 4′,6′-diamidino-2-phenylindole (Molecular Probes).
Results
Preparation and Characterization of Medulloblastoma Cell Line from Immune-Competent Mice
To make an MV-susceptible immune-competent mouse model of medulloblastoma, Prom1+ cerebellar stem cells from P6 hCD46TgIC mice were transfected to express SVC, and murine stabilized Myc and Gfi1b proteins. The stable cells grow as neurospheres in the presence of bFGF and EGF and express Myc and Gfi1b as shown by the florescence of conjugated markers tdT and GFP, respectively (Fig. 1A) . Next, we examined if these cells are tumorigenic in mice. No tumor could be detected when cells
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were implanted directly from culture into the cerebellum of hCD46TgIC mice. However, when injected into the cerebellum of immune-deficient NSG mice, large tumors were formed. A cell line, CSCG, was established from the NSG tumors. CSCG cells were highly tumorigenic when injected into the brains of hCD46TgIC mice (Fig. 1B) . The immunoblotting of total cell lysates confirmed overexpression of Myc and Gfi1b proteins in CSCG in comparison to CS cells (Fig. 1C) . The expression of Gfi1, MycN, and p53 remained unchanged after modification with Myc and Gfi1b.
The rate of proliferation of CSCG cells was compared with that of CS cells. The number of live CSCG cells increased by 19-fold in 72 hours (equivalent to more than 4 population doublings), whereas CS cells, expressing SVC but not Myc and Gfi1b, showed only a 3.4-fold increase (less than 2 doublings) in the same period ( Fig. 2A) . This suggests that Myc and Gfi1b, and not SVC, drives the high proliferation of CSCG cells.
The ability of self-renewal is a putative characteristic of stem cells. When seeded at a subclonal density (2 cells/mm 2 ) in NBA media, single CSCG cells formed neurospheres in as early as 96 h after seeding (Fig. 2B) . The sphere-forming ability of single CSCG cells was monitored for 4 consecutive weeks after repeated dissociation and reseeding suggesting stem cell-like behavior of CSCG cells (data not shown). In addition, these cells show positive immunofluorescence staining for the proliferation marker Ki67, sex determining region Y-box 2 (Sox2), and nestin, proteins widely used as markers for neural stem cells (Fig. 2C) . The quantification of positive cell staining by flow cytometry showed that 94.9%, 98.7%, and 93% of cells expressed Ki67, Sox2, and nestin markers, respectively (Fig. 2C) .
MV Replicates in and Kills CSCG Cells
We verified by flow cytometry that CS cells express high levels of human MV receptor CD46 on the cell surface (Fig. 3A) . To determine that CSCG cells allow replication of measles virus, cells were infected at MOI 0.1 and the titer of infectious virus particles was quantified at 24-h intervals for 4 days. The titer increased with time, peaking at 72 h and then dropping at 96 h, presumably due to extensive cell death caused by the replicating virus (Fig. 3B) .
CSCG cells are highly susceptible to measles virus (MV-GFP) in a dose-dependent manner. Infection with an MOI 0.1, 1, and 10 killed 55%, 85%, and 92% of cells, respectively, after 96 h of incubation (Fig. 3C) . Similarly, a time-dependent increase in cell killing with 49% at 24 h, and 92% at 96 h postinfection was observed when CSCG cells were infected at MOI 1 with MV-GFP (Fig. 3D) . These results show that CSCG cells allow replication of and are killed by MV.
MV Significantly Increases Survival of CSCG Tumor-Bearing Mice
CSCG cells (2 × 10 5 /mouse) were implanted in the brains of hCD46TgIC mice, and BLI was recorded to monitor tumor growth. When the BLI intensity increased by 10-to 20-fold higher than initial value, mice were randomized and treated with a single intratumoral injection of 1.5 × 10 5 TCID 50 of live MV-GFP or HI-MV. Another set of mice were included that received equal volume of PBS as a control. Animals were monitored for tumor regression and survival. The decrease in the intensity of luciferase bioluminescence of CSCG cells demonstrated that mice treated with MV-GFP exhibited a significant decrease in tumor burden compared with mice in control groups (Fig. 4A ). Mice treated with MV-GFP had significantly prolonged survival compared with animals that received HI-MV (log-rank test P = 0.0027) or PBS (logrank test P = 0.0018). The median survival for PBS-treated and HI-MV-injected mice was 32 days ± 4.5d, and 34 days ± 2.9d (log-rank test P = 0.5273), respectively (Fig. 4B) . In the MV-treatment group, 3 out of 5 animals had complete tumor regression and remained alive and free of tumor for the maximum period of the study (150 days), hence median survival could not be calculated. One mouse in this group had transient abolition of tumor for 9 weeks posttreatment before tumor recurred and the mouse died after 84 days. The last mouse in this group also showed complete tumor regression but died because of intracranial hemorrhage due to an unknown reason at 60 days posttreatment. One mouse in the HI-MV-treated group suffered excessive bleeding and died after virus injection, hence was excluded from the analysis. 
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In the brains of mice treated with either PBS or HI-MV, hematoxylin and eosin (H&E) sections revealed large primitive neuroepithelial tumors composed of densely packed small, round, undifferentiated cells with mild nuclear pleomorphism, numerous mitotic figures, and scattered apoptotic bodies. In contrast, no tumor cells were evident in MV-treated mice brains (Fig. 5A) .
On the molecular level, western blotting demonstrated that CSCG tumors express higher levels of the well-established Group 3 medulloblastoma markers, NPR3 and GABRA5, compared with CS cells (Fig. 5B) . Immunohistochemistry of brain tissues exhibited high expression of NPR3 and GABRA5 in CSCG tumor cells, whereas the nontumor (NT) regions remained negative for these markers (Fig. 5C) . Also, we did not observe any sign of increased apoptosis in Myc-transformed CSCG cells (Fig. 5B) . These results suggest that CSCG cells grow and form tumors in the brains of immune-competent mice and are killed by MV in vivo, and that the CSCG tumors represent the highly aggressive Group 3 subtype of medulloblastoma.
Discussion
The preclinical efficacy of oncolytic MV against medulloblastoma 15,16 and many other cancer types 28 has been shown, but those studies were done in immune-compromised xenograft models. Given that anti-measles immunity is prevalent in the human population, results from immunodeficient models may not translate to human disease. The lack of any immune-competent murine model has been an obstacle to investigating the effect of the immune system on MV antitumor therapy of medulloblastoma. The biosafety of intracerebral and intrathecal injection of Edmonston vaccine strain of measles virus has been extensively evaluated in preclinical models including transgenic measles-sensitive mice and rhesus macaques. [29] [30] [31] [32] No evidence of systemic clinical or biochemical toxicity, behavioral symptoms, or neurotoxicity was observed in these studies, which laid the foundation for investigation of modified MVs in several clinical trials in both solid and hematological cancers. 33 Among the 4 molecularly distinct subtypes of medulloblastoma, Group 3 tumors have the worst prognosis. 24 The overexpression of MYC and GFI1/GFI1B has been reported as driver events in these highly aggressive tumors. 25 In this paper, we report the successful manufacture of a murine cell line that mimics Group 3 medulloblastoma and is permissive for the infection and replication of oncolytic MV. In addition, this cell line forms rapidly growing tumors in the mouse brain. These tumors can be effectively treated with MV in these immune-competent mice.
The starting cells for the CSCG cell line are cerebellar stem cells isolated from transgenic mice expressing human CD46, the receptor for the Edmonston strain of measles virus in humans. 34 Thus, by using these transgenic mice, we overcame the first barrier to growth of MV in murine cells. The P-gene of MV also encodes for 2 nonstructural proteins, V and C proteins. The V protein of MV binds to and inactivates the Stat1/Stat2 complex in human cells. 21, 35, 36 Interferon signaling activates this complex, and MV requires prevention of complex activity for replication. Because the measles virus V protein does not bind to murine Stat1/Stat2, MV does not replicate well in murine cells, because the complex remains active. To overcome this barrier, we transduced cells with the SVC. This protein has the same function as the V protein of MV, but it does bind to and inactivate the murine Stat1/Stat2 complex. 22, 23 Therefore, the cell line reported here is infectable by MV, as it expresses the human MV receptor and is permissive for replication of MV, as the activity of the Stat1/Stat2 complex is prevented by SVC. This cell line and the model presented here can be used to examine the interaction of MV and the intact immune system. We recognize that the expression of the SVC protein may induce an immune response in host mice. This will be investigated in our ongoing studies of the effect of the immune system on MV therapy in this model. Pei et al and Kawauchi et al reported that overexpression of Myc in TP53-deficient mice or in mice with dominant negative p53 protein forms tumors with a high degree of similarity to human Group 3 medulloblastoma in terms of gene expression profile and molecular pathology. 37, 38 However, Tabori et al showed that in clinical samples none of the TP53-mutated tumors showed MYC amplification and that tumors with TP53 mutation presented with aggressive but locally recurrent disease. 39 Though mutation or deficiency of p53 is associated with a negative prognosis, these alterations are almost exclusively present in the sonic hedgehog and Wnt subtypes of medulloblastoma. 24, [40] [41] [42] In comparison, the CSCG cell line presented here has intact p53 and forms rapidly growing tumors with elevated expression of NPR3 and GABRA5 (Fig. 5B, C) , molecular markers of Group 3 medulloblastoma. 43 , 44 Pei et al reported that cell lines with overexpression of Myc had high rates of apoptosis and, thus, were not tumorigenic in mice. 37 However, CSCG cells do not show increased signs of apoptosis compared with parental cells that expresses SVC, but not Myc and Gfi1b proteins (Fig. 5B) .
To study the pathogenesis and antitumor efficacy of MV oncolysis, transgenic mouse strains have been developed with either organ-specific or ubiquitous expression of human CD46 receptor and/or inhibition of the innate interferon pathway. 45 However, in most of these models, MV failed to grow in the brain. 46 Therefore, studies in immunecompetent murine models have been limited to using retargeted MVs armed with a cytotoxic prodrug-convertase with 
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cyclophosphamide immunosuppression in a subcutaneous colon carcinoma model, 47 or using a CD20-retargeted MV encoding antibodies against cytotoxic T lymphocyte antigen 4 and programmed death ligand 1 in a melanoma model. 48 However, the replication of retargeted virus was limited in murine cells, and the efficacy was dependent on the therapeutic genes in the engineered viral genome.
The CSCG murine medulloblastoma cell line described in this paper allows efficient intracellular replication of MV due to SVC-mediated inactivation of the interferon pathway. Experiments are ongoing to assess the antitumor efficacy of MV on CSCG tumors in measles-naive and measles-immune animals. This model is well suited to examine the positive or negative effects of the intact immune system on the therapeutic efficacy of MV. In human patients, leptomeningeal dissemination of tumor cells is diagnosed at a higher rate in Group 3 and 4 medulloblastoma. 49 However, in the CSCG model, we did not find evidence of leptomeningeal spread of tumor cells by bioluminescence imaging. This could be because tumor grew aggressively and animals died quickly after tumor cell implantation.
In conclusion, CSCG cells represent the first murine tumor cell line and tumor model of any tumor type that is permissive for MV replication and that grows in immunecompetent mice. Importantly, the strategies used here are easily generalizable to other tumor types for which the driving mutations are known. 
